Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trialZefei Jiang, Yuan Sheng, Quchang Ouyang et al.|Nature Medicine|2024Cited by 121
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lü, Shucai Zhang, Gang Wu et al.|Journal of Thoracic Oncology|2022Cited by 25
TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).Zefei Jiang, Quchang Ouyang, Tao Sun et al.|Journal of Clinical Oncology|2023Cited by 5
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancerYuan Sheng, Quchang Ouyang, Tao Sun et al.|Future Oncology|2024Cited by 1